Y Intercept Hong Kong Ltd Acquires 10,577 Shares of Novo Nordisk A/S $NVO

Y Intercept Hong Kong Ltd lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 99.1% in the third quarter, Holdings Channel.com reports. The fund owned 21,245 shares of the company’s stock after purchasing an additional 10,577 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Novo Nordisk A/S were worth $1,179,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Revolve Wealth Partners LLC raised its holdings in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Novo Nordisk A/S by 21.0% during the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after buying an additional 10,758 shares during the period. Sivia Capital Partners LLC raised its stake in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in Novo Nordisk A/S by 1.1% in the second quarter. Janney Montgomery Scott LLC now owns 156,117 shares of the company’s stock worth $10,775,000 after buying an additional 1,699 shares during the period. Finally, Pure Financial Advisors LLC bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $242,000. Institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Very strong launch demand for Wegovy pill: IQVIA data show the pill tracked over 26,000 U.S. prescriptions in its second full week, signaling rapid uptake that supports revenue upside and market share gains in the obesity market. Novo’s Wegovy pill tracks over 26,000 prescriptions
• Positive Sentiment: Early sales momentum reinforced by reporting of ~18,000 U.S. prescriptions in week one and commentary that demand is “strong out of the gate,” which supports upside to near‑term sales and investor sentiment. Demand for Novo Nordisk’s Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
• Neutral Sentiment: Analyst view is mixed — one upgrade highlights first‑mover advantage, strong cash and aggressive U.S. marketing but also flags high valuation and potential for near‑term profit‑taking, leading to a cautious “Hold” posture. Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
• Neutral Sentiment: Public profile of Novo’s weight‑loss boom is increasing (e.g., a new Danish theatre piece), which is PR‑positive but not directly material to near‑term financials. New play in Denmark charts Novo Nordisk’s weight loss boom
• Negative Sentiment: Leadership change in China: Senior VP and head of China Christine Zhou will step down at end‑of‑March — a potential disruption given China’s importance for growth and ongoing market expansion. Novo Nordisk’s China President Zhou to step down in March
• Negative Sentiment: Near‑term headwinds flagged: analysts warn of slowing Wegovy/Ozempic momentum, pricing pressure and stronger competition that could limit upside to sales growth and margins into the Q4 earnings release. Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $59.40 on Friday. The company has a market capitalization of $265.23 billion, a price-to-earnings ratio of 17.27 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80. The company’s 50-day moving average is $53.44 and its 200 day moving average is $54.41.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The firm had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NVO has been the subject of several research reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. HSBC reaffirmed a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Morgan Stanley reissued an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of Novo Nordisk A/S in a research note on Monday, October 27th. They issued an “underperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.